---
title: "Randomized, Placebo-Controlled Trial of N-acetylcysteine In Parkinson's Disease Patients: A Pilot Study"
nct_id: NCT07093944
overall_status: COMPLETED
phase: PHASE2
sponsor: Kurdistan University of Medical Sciences
study_type: INTERVENTIONAL
primary_condition: "Parkinson's Disease (PD)"
countries: Iran
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07093944.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07093944"
ct_last_update_post_date: 2025-07-30
last_seen_at: "2026-05-12T06:35:05.513Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Randomized, Placebo-Controlled Trial of N-acetylcysteine In Parkinson's Disease Patients: A Pilot Study

**Official Title:** Effect of N-acetyl Cysteine as an Adjuvant Therapy on Symptoms and Progression of Parkinson's Disease

**NCT ID:** [NCT07093944](https://clinicaltrials.gov/study/NCT07093944)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 42
- **Lead Sponsor:** Kurdistan University of Medical Sciences
- **Conditions:** Parkinson's Disease (PD)
- **Start Date:** 2018-04-09
- **Completion Date:** 2021-12-22
- **CT.gov Last Update:** 2025-07-30

## Brief Summary

This is a study on Parkinson's disease patients, referred to Tohid Hospital of Sanandaj City. The patients receive N-acetylcysteine for one year. The efficacy of the Drug is evaluated based on clinical interview, filling Unified Parkinson's Disease Rating Scale (UPDRS) questionnaire, and single-photon emission computerized tomography (SPECT) brain imaging. The only person who has not been blinded for the study is the supplier of the drug and placebo.

Inclusion criteria: Patient's informed consent Exclusion criteria: Having brain surgery within a year before the initiation of the intervention.

Medication group: receiving 1200 mg N-acetylcysteine per day, twice daily, each time 600 mg.

placebo group: receiving a placebo with similar appearance, color, odor, and taste like real medication.

## Detailed Description

This is a randomized double-blinded clinical trial. Randomization method is based on making blocks with size of 4 people, to divide participants into two groups: intervention group (A) and control group (B). So that, we divide all participants to four-sample blocks, and we allocate the block's samples equally between the two groups (e.g. ABAB). This pattern is the same in all blocks. Participants, clinical caregivers, outcome evaluators and data analyzers are not aware whether the therapeutic regimens include the drug or placebo. only the main researcher and pharmacist are aware of nature of therapeutic regimen based on codes given to the drug and placebo packages, earlier.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patient's informed consent No brain surgery in the patient's post medical history

Exclusion Criteria:

* having brain surgery within a year before starting the treatment period
```

## Arms

- **Medication group** (EXPERIMENTAL) — Receiving 1200 mg N-acetylcysteine per day, twice daily, each time 600 mg
- **Placebo group** (PLACEBO_COMPARATOR) — Receiving a placebo with similar appearance, color, odor, and taste like real medication

## Interventions

- **N-Acetylcysteine (NAC) Treatment** (DRUG) — Parkinson's disease patients receive NAC (1200 mg/day) for one year.
- **Placebo** (DRUG) — Parkinson's disease patients receive Placebo similar to the real drug, with no active ingredient

## Primary Outcomes

- **single-photon emission computerized tomography (SPECT) brain imaging** _(time frame: one year)_ — Also known as TRODAT scan or DaTscan, is a nuclear medicine imaging procedure that helps diagnose and evaluate Parkinson's disease by assessing the function of dopamine transporters in the brain. It specifically visualizes the dopaminergic system, which is affected in Parkinson's disease.
- **Unified Parkinson's Disease Rating Scale (UPDRS)** _(time frame: one year for each PD patient (at baseline and after one year))_ — It is a questionnaire to assess the severity and progression of Parkinson's disease.

## Locations (1)

- Kurdistan University of Medical Sciences, Sanandaj, Kurdistan Province, Iran

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.kurdistan university of medical sciences|sanandaj|kurdistan province|iran` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07093944.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07093944*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*